Early detection of acute and early-onset cardiovascuLar toxicity in children with cancer using a multiparametric approach.

Princess Maxima Center0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria;
•We will include 2 groups of CC patients in our study:
•1)100 CC patients receiving anthracyclines as part of their cancer treatment in the Princess Máxima Center for Pediatric Oncology (group 1).
•2)A subgroup of 30 CC patients aged > 8 years, diagnosed with HL, ES, OS or STS, receiving anthracyclines as part of their cancer treatment and will undergo MRI evaluation as part of their tumor response evaluation. (group 2).
•All children and/or their parents will be asked for informed consent for cardiac screening with the described multimodality approach using echocardiography, ECG and future cardiac blood biomarkers and genetic testing. Patients who meet the inclusion criteria for group 2, will be asked for an additional informed consent to also undergo cardiac MRI.

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•Exclusion criteria are children with severe comorbidity (being too sick for evaluation), history of thoracic radiation or chemotherapy for other malignancies, general contraindications for MRI for the patients in the MRI study group. Patients who need anaesthesia for MRI scanning will be excluded from the study.

发起方

Princess Maxima Center